ATAXIA UK — grant history
Latest income
£1.8m
Grants listed (FY2025)
2
Listed grants total
£78k
Accounts grants total
£78k
listed grants reconcile with the accounts totalextracted from its FY2025 accounts
Application guidance — from the funder’s own website
- How to apply: Ataxia UK does not accept unsolicited applications for research grants. The charity funds a wide variety of research projects, but the specific process for researchers to apply is not detailed on the provided pages, which only list currently funded projects.
What changed: FY2024 → FY2025
| Change | Grantee | FY2024 | FY2025 |
|---|---|---|---|
| new | Z-Institut du Cerveau et de laMoelle épinière-ICM | — | £68k |
| new | Z-Universidade de Lisboa | — | £10k |
| not listed | Dr Shiloh-Malawsky (University of North Carolina, US) | £35k | — |
| not listed | Dr Hubener-Schmid (University of Tubingen, Germany) | £30k | — |
| not listed | Prof Tremblay (Universite’ Laval, Canada) | £8k | — |
| not listed | Realise Advocacy consultancy | £6k | — |
| not listed | Dr Abeti and Prof Giunti (UCL, UK) | £5k | — |
| not listed | Dr Anjoumani-Virmouni (Brunel University) | £5k | — |
| not listed | Prof Clayton (Great Ormond Street Institute of Child Health, UK) | £5k | — |
| not listed | Dr Hauser (DZNE, Germany) | £4k | — |
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Z-Institut du Cerveau et de laMoelle épinière-ICM | FY2025 | £68k | Novel biomarkers of oxidative stress in ataxia; Identification of disease-associated single nucleotide polymorphisms in ataxin-3; Evaluating ribosome collisions on CAG expansions proteostasis and translational; Consultancy support with respect to preparing for Health Technology Assessment; Effect of targeting sphingolipid- metabolising enzymes in iPSC-derived sensory neurons model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) |
| Z-Universidade de Lisboa | FY2025 | £10k | Restoring NKX6-2 function by protein complementation: a proof-of-concept; Outcome measures in Mitochondrial disease and Spinocerebellar ataxias (R-PROMS) |
| Dr Shiloh-Malawsky (University of North Carolina, US) | FY2024 | £35k | Extension project “DRPLA Natural History and Biomarkers Study |
| Dr Hubener-Schmid (University of Tubingen, Germany) | FY2024 | £30k | Development and Validation of SIMOA-based total and mutant Ataxin-2 Immunoassay for biomarker studies in SCA2 and SCA3 |
| Prof Tremblay (Universite’ Laval, Canada) | FY2024 | £8k | Novel biomarkers of oxidative stress in Friedreich's ataxia |
| Realise Advocacy consultancy | FY2024 | £6k | Preparing for the health technology assessment process in FA |
| Dr Abeti and Prof Giunti (UCL, UK) | FY2024 | £5k | Exploring novel iron-mediated mechanisms to prevent cellular death in Friedreich’s ataxia |
| Dr Anjoumani-Virmouni (Brunel University) | FY2024 | £5k | Effect of targeting sphingolipid-metabolising enzymes in iPSC derived sensory neurones obtained from FRDA patients |
| Prof Clayton (Great Ormond Street Institute of Child Health, UK) | FY2024 | £5k | Novel biomarkers of oxidative stress in Friedreich’s ataxia |
| Dr Hauser (DZNE, Germany) | FY2024 | £4k | Identification of disease-associated single nucleotide polymorphisms in ataxin-3 |
| Dr Matassa University of Naples, Italy | FY2024 | £3k | Evaluating ribosome collisions on CAG expansions proteostasis and translational stress responses in Spinocerebellar Ataxia type 3 |
| Prof Marios Hadjivassiliou (Sheffield Teaching Hospitals NHS Trust, UK) | FY2023 | £38k | Improving the diagnosis and management of gluten ataxia |
| Dr Karen Anthony (University of Northampton, UK) | FY2023 | £31k | Evaluation of RNA trans-splicing as a therapeutic strategy for spinocerebellar ataxia type 1 |
| Dr Andreia Teixeira-Castro (University of Minho, Portugal) | FY2023 | £30k | Testing the multimodal anti-depressant vortioxetine as a therapeutic strategy to mitigate SCA3 |
| Dr Roderick Maas (Radboud University Medical Center, The Netherlands) | FY2023 | £30k | Looking beyond the central nervous system in SCA3: nerve and muscle ultrasound as potential imaging markers to quantify and monitor peripheral nervous system degeneration. |
| Prof Paola Giunti (University College London, UK) | FY2023 | £27k | Validating the therapeutic effect, a CAG repeat-targeting antisense oligonucleotide, on mitochondrial physiology in cellular models of DRPLA |
| Prof Paola Giunti (University College London, UK) | FY2023 | £25k | Determine mitochondrial metabolism in DRPLA: a possible novel therapeutic approach |
| UK Researchers | FY2023 | Unverified read£7k | Nine bursaries of £750 each to UK researchers to help them attend the International Congress for Ataxia Research |
| Dr Francesca Salvatori (University of Ferrara, Italy) | FY2023 | £5k | Personalized gene editing approach for the treatment of Spinocerebellar Ataxia type 1 (SCA1) |
| Dr Pellerin (UCL) | FY2023 | £2k | Dr David Pellerin travel grant award of £1500 to attend and present an oral presentation at the American Academy of Neurology 2023 Annual Meeting. |
| Gordon Research Conference | FY2023 | £433 | $500 Sponsorship of CAG Triplet Repeat Disorders Gordon Research Conf and Seminar |
| University of North Carolina at Chapel Hill, USA | FY2022 | £131k | DRPLA Natural History and Biomarkers Study (DRPLA NHBS) |
| German Center for Neurodegenerative Diseases, Bonn, Germany | FY2022 | £80k | Assessment of ataxia severity under real-life conditions with SARAhome: A multicenter study in spinocerebellar ataxia type 3 (SCA3) |
| Institut du Cerveau et de la Moelle épinière (ICM), France | FY2022 | Unverified read£61k | Preclinical development of an amelioration therapy for DentatorubroPallidoluysian Atrophy – Funding Extension |
| Instituto de Invesigacão e Inovacão em Saúde – i3S, Portugal | FY2022 | £30k | NanoSCA3: Development of brain-targeted nanobodies for application in spinocerebellar ataxia type 3 therapy |
| University College London, UK | FY2022 | £5k | Brain pathology in an AIFM1 mutation causing Cowchock syndrome |
| Imperial College London, UK | FY2022 | £5k | Generation and characterization of a cardiomyocyte model for Friedreich’s ataxia to reveal the molecular mechanism of heart failure in patients |
| University of Brescia, Italy | FY2022 | £5k | Motor and cognitive outcomes of non-invasive transcranial alternate current stimulation by entrainment of cerebellar oscillation |
| Newcastle University, UK | FY2022 | £5k | Balance and gait abnormalities in adult patients with mitochondrial disease and spinocerebellar ataxia type 6 |
| Centro de Biología Molecular Severo Ochoa, Madrid, Spain | FY2022 | £5k | Analysis of the mitochondrial dysfunction in FXN deficient neurones to generate a drug screening test |
| Strathclyde University, UK | FY2022 | £3k | A feasibility study of LSVT Artic to improve speech performance in people with progressive ataxia |
| Prof Paola Giunti (University College London, UK) | FY2021 | Unverified read£1.0m | Comprehensive Biomarker Characterisation in Dentatorubral-Pallidoluysian Atrophy |
| Prof Henry Houlden (University College London, UK) | FY2021 | £492k | Biomarkers, Somatic Instability and creating a DRPLA cell line resource |
| Dr Heather Lau (NYU Grossman School of Medicine, USA) | FY2021 | £126k | The DRPLA Natural History and Biomarker Study |
| Prof Louise Corben (Genetic Health Research & Murdoch Children's Research Institute, Australia) | FY2021 | £71k | Investigating the use of the Ataxia Instrumented Measure – Spoon in measuring upper limb function in DRPLA |
| Dr Chelban and Prof Holden (UCL Institute of Neurology, London) | FY2021 | £70k | NKX6-2 Related Spastic Ataxia and Leukodystrophy: Natural history, biomarkers and the potential of gene transfer method |
| Prof Adam Vogel (Redenlab &The University of Melbourne, Australia) | FY2021 | £51k | Redenlab Scope of Work for the DRPLA Natural History Study (Speech and Dysphagia) |
| Dr Tremblay (Laval University, Canada) | FY2021 | £35k | Development of a PRIME editing therapy for Ataxia-8 due to the c.121 A to T point mutation |
| Dr Filip Lim (University of Madrid, Spain) | FY2021 | £30k | Generating new Friedreich’s Ataxia animal models for validating HSV-1 FXN gene therapy in Dorsal Root Ganglia Dr Lim |
| Dr D’Autreax (CNRS-CEA-Université Paris-Saclay, France) | FY2021 | £26k | Development of a selective high throughput screening assay for the discovery of compounds replacing frataxin in FA |
| Dr Rufini, Fratagene Therapeutics (University of Rome) | FY2021 | £20k | Etravirine as a potential therapeutic for Friedreich ataxia |
| Prof Lowit | FY2021 | £6k | A joint model of online Speech and language therapy intervention and peer support to enhance communication effectiveness and participation in people with progressive ataxia |
| Prof Horvath (Cambridge, UK) | FY2021 | £5k | PROSPAX: an integrated multimodal progression chart in spastic ataxias |